Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Tuberculosis and HIV news

Show

From To
CROI 2015: Trial to evaluate the use of health navigators to link HIV/TB patients to care and treatment fails to show positive results

Patients randomized to the support of a health navigator were not more likely than those who received standard of care to complete tuberculosis treatment or begin antiretroviral therapy within three months of HIV diagnosis, according to the results of a South African randomized trial presented here today.

Published
26 February 2015
From
Science Speaks
Starting HIV treatment at CD4 count above 500 reduces the risk of serious illness and death by 44%, African Temprano trial shows

Starting HIV treatment at a CD4 cell count above 500 reduced the risk of serious illness including tuberculosis (TB), and death, by 44% when compared to starting

Published
26 February 2015
By
Keith Alcorn
XDR-TB in South Africa is largely spread person-to-person, not by failure of drug treatment

The vast majority of people with extensively drug-resistant tuberculosis (XDR-TB) diagnosed in the world’s most extensive outbreak have acquired their infection from another person, not as the

Published
26 February 2015
By
Keith Alcorn
UGA researchers discover potential treatment for drug-resistant tuberculosis

The compound Nair and his colleagues developed works by binding to magnesium and specific amino acids found within the bacterium, interrupting the production of RNA. They were surprised to discover through preliminary experiments that it also exhibited strong anti-HIV properties, opening the door for dual therapeutic applications.

Published
20 February 2015
From
University of Georgia press release
TB drug candidate starts Phase 1 trial — first in six years

The enrollment of nearly 50 volunteers in the United States will launch the first randomized clinical trial of a potential  new drug to treat TB in six years, the nonprofit product development partnership TB Alliance announced Wednesday.

Published
20 February 2015
From
Science Speaks
Fighting tuberculosis in the European region requires urgent support. Take action today!

Today, the TB Europe Coalition, with the support of Stop TB Partnership, launches the Fight TB 2015 campaign to ensure that European leaders step up their response to TB to save millions of lives.

Published
18 February 2015
From
TB Europe Coalition
South Africa: Pledge to turn tide in the war on TB

A massive tuberculosis screening programme to the tune of half a billion rand will begin next month, covering three areas of society most vulnerable to the disease, Health Minister Aaron Motsoaledi said yesterday at a briefing held in Pretoria. Every prisoner in the country will be screened for tuberculosis from next month. If inmates test positive, their families will be tracked and also tested for the disease. There are over 150,000 prisoners in South Africa.

Published
17 February 2015
From
Times Live
Addressing TB and drug-resistant TB in the Eastern Ukrainian region

The challenges in addressing the implementation of comprehensive HIV, TB and viral hepatitis prevention and treatment activities in the Eastern Ukraine affected by the warfare is complicated and escalating every week.

Published
11 February 2015
From
Stop TB Partnership
Obama Budget Boosts U.S. HIV and Hepatitis Funding, Cuts Global AIDS and TB

President Obama's proposed $4 trillion budget for fiscal year 2016 would increase funding for CDC's viral hepatitis and HIV prevention efforts, boost spending for HIV research, and allocate more to combat antibiotic resistance. But the plan would cut overall global health funding, including support for the Global Fund to Fight AIDS, Malaria, and Tuberculosis.

Published
09 February 2015
From
HIVandHepatitis.com
Access sought to tuberculosis drug from nutraceutical company

Delamanid, only the second tuberculosis drug approved in 40 years by European regulators, uses a new mechanism of action to treat the disease by inhibiting the synthesis of a cell-wall component of Mycobacterium tuberculosis, the bacterium that causes tuberculosis. But patient advocates worry that the new drug may not reach the patients who need it because, according to these advocates, the developer of the drug has failed to aggressively study and market the medication in regions that need it most.

Published
05 February 2015
From
Nature Medicine

Filter by country